A detailed history of Opaleye Management Inc. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Opaleye Management Inc. holds 112,500 shares of CPRX stock, worth $2.44 Million. This represents 0.41% of its overall portfolio holdings.

Number of Shares
112,500
Previous 640,000 82.42%
Holding current value
$2.44 Million
Previous $9.91 Million 77.44%
% of portfolio
0.41%
Previous 2.54%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$15.19 - $21.35 $8.01 Million - $11.3 Million
-527,500 Reduced 82.42%
112,500 $2.24 Million
Q2 2024

Aug 14, 2024

SELL
$14.68 - $16.92 $5.35 Million - $6.16 Million
-364,355 Reduced 36.28%
640,000 $9.91 Million
Q1 2024

May 15, 2024

SELL
$13.18 - $17.11 $3.33 Million - $4.33 Million
-252,845 Reduced 20.11%
1,004,355 $16 Million
Q4 2023

Feb 14, 2024

BUY
$11.78 - $17.29 $614,916 - $902,538
52,200 Added 4.33%
1,257,200 $21.1 Million
Q3 2023

Nov 14, 2023

BUY
$11.69 - $15.02 $14.1 Million - $18.1 Million
1,205,000 New
1,205,000 $14.1 Million
Q3 2020

Nov 16, 2020

SELL
$2.97 - $5.08 $3.43 Million - $5.87 Million
-1,155,000 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$3.48 - $5.05 $365,400 - $530,250
105,000 Added 10.0%
1,155,000 $5.34 Million
Q1 2020

May 15, 2020

BUY
$2.61 - $5.21 $2.74 Million - $5.47 Million
1,050,000 New
1,050,000 $4.04 Million
Q2 2019

Aug 14, 2019

SELL
$2.7 - $6.11 $4.93 Million - $11.2 Million
-1,825,000 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$2.11 - $5.33 $3.85 Million - $9.73 Million
1,825,000 New
1,825,000 $9.31 Million

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.23B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Opaleye Management Inc. Portfolio

Follow Opaleye Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Opaleye Management Inc. with notifications on news.